DLL4 Gene — Delta-Like 4
Overview
Mermaid diagram (expand to render)
DLL4 (Delta-Like 4) is a critical Notch ligand that plays essential roles in vascular development, blood-brain barrier formation, and neural stem cell function. This gene has emerged as a significant player in neurodegenerative disease pathogenesis, particularly through its effects on the neurovascular unit and cerebral vasculature. DLL4-Notch signaling represents a key intersection between vascular biology and neurodegeneration in conditions like Alzheimer's disease, Parkinson's disease, and cerebral autosomal dominant arteriopathy with subcortical infarcts (CADASIL).
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">DLL4 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>DLL4</td></tr>
<tr><td><strong>Full Name</strong></td><td>Delta-Like 4</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>15q15.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[54567](https://www.ncbi.nlm.nih.gov/gene/54567)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[609967](https://www.omim.org/entry/609967)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000128917</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9NRF0](https://www.uniprot.org/uniprot/Q9NRF0)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>CADASIL, Alzheimer's Disease, Cancer, Vascular Dysfunction</td></tr>
</table>
</div>
Molecular Biology and Function
Protein Structure
DLL4 encodes a transmembrane protein of approximately 685 amino acids belonging to the Delta-like family of Notch ligands. The protein contains:
N-terminal DSL domain: Essential for interaction with Notch receptors
EGF-like repeats: Eight epidermal growth factor-like repeats that mediate ligand-receptor binding specificity
Transmembrane domain: Anchors the protein to the cell membrane
C-terminal intracellular domain: Involved in signal transduction and protein traffickingThe DSL (Delta-Serrate-Lag-2) domain is conserved across all Notch ligands and is required for functional interaction with Notch receptors [@dll42005].
Signaling Mechanism
DLL4 activates Notch signaling through direct cell-cell contact:
Ligand presentation: DLL4 on the surface of one cell engages Notch receptors on adjacent cells
Receptor activation: Binding triggers sequential proteolytic cleavages of Notch
NICD release: The Notch intracellular domain (NICD) is released
Transcriptional regulation: NICD translocates to the nucleus and, with RBPJ, activates target genes including HES1, HEY1, and HEY2DLL4 exhibits unique signaling properties compared to other Notch ligands:
- Tip cell specification: DLL4-Notch signaling is critical for tip cell formation during angiogenesis
- Iterative signaling: DLL4 can undergo regulated intramembrane proteolysis (RIP)
- Fringe modification: DLL4-Notch interactions are modulated by glycosyltransferases
Expression Pattern
DLL4 is expressed in multiple tissues with particularly important roles in:
Vascular system: Highest expression in arterial endothelial cells, where it regulates:
- Tip cell formation and guidance
- Sprouting angiogenesis
- Vessel branching and patterning
- Arterial-venous specification
Nervous system: Expressed in:
- Neural stem cells in the subventricular zone and subgranular zone
- Neurons in specific brain regions
- Brain endothelial cells
- Pericytes and vascular smooth muscle cells
Role in Neurodegeneration
Alzheimer's Disease
DLL4-Notch signaling plays multifaceted roles in Alzheimer's disease through effects on the neurovascular unit:
Blood-Brain Barrier Integrity: DLL4 critically regulates BBB formation and maintenance [@dll42008][@bbb2020]:
- Controls endothelial cell junction formation
- Regulates tight junction protein expression (claudin-5, occludin, ZO-1)
- Modulates transporter expression (P-glycoprotein, GLUT1)
- Influences pericyte coverage and function
In AD, altered DLL4 signaling contributes to BBB breakdown, allowing peripheral molecules to enter the brain and contributing to neuroinflammation.
Amyloid-Vascular Interactions: DLL4-Notch signaling intersects with amyloid pathology in several ways [@amyloid2021]:
- Notch and APP processing share common proteases (gamma-secretase)
- Altered blood flow due to DLL4 dysfunction affects amyloid clearance
- Vascular dysfunction promotes amyloid deposition in cerebral vasculature (CAA)
- Endothelial DLL4 expression can be modulated by amyloid-beta
Neurogenesis and Neural Stem Cells: DLL4 regulates adult neurogenesis [@dll42010][@neurogenesis2021]:
- Maintains neural stem cell pools in the hippocampus and subventricular zone
- Promotes astrogenesis over neurogenesis under certain conditions
- Altered DLL4 signaling may contribute to reduced neurogenesis in AD
- Modulates inflammatory responses in the neurogenic niches
Parkinson's Disease
In Parkinson's disease, DLL4-Notch signaling affects:
Dopaminergic Neuron Survival: Notch ligands including DLL4 influence:
- Development and maintenance of dopaminergic neurons
- Vulnerability to oxidative stress
- Mitochondrial function
Vascular Function: Altered cerebrovascular function in PD:
- Reduced cerebral blood flow
- Altered neurovascular coupling
- Vascular contributions to alpha-synuclein pathology
CADASIL
DLL4 represents a particularly important therapeutic target in CADASIL [@cadasal2018]:
- NOTCH3 mutations cause CADASIL, a hereditary small vessel disease
- DLL4-Notch3 signaling regulates vascular smooth muscle cell function
- Altered DLL4 signaling contributes to:
- Vessel wall thickening
- Reduced cerebral blood flow
- White matter lesions
- Subcortical infarcts
Understanding DLL4-Notch3 interactions may provide insights into both hereditary and sporadic small vessel diseases.
Neuroinflammation
DLL4-Notch signaling modulates neuroinflammatory responses [@neuroinflammation2020]:
- Regulates microglial activation and cytokine production
- Affects astrocyte reactivity
- Modulates peripheral immune cell infiltration
- Influences the balance between pro- and anti-inflammatory states
Therapeutic Implications
Targeting DLL4-Notch Signaling
The DLL4-Notch pathway offers several therapeutic opportunities:
Anti-DLL4 antibodies: Monoclonal antibodies blocking DLL4-Notch interactions:
- Tested in cancer clinical trials
- Potential for vascular modulation in neurodegeneration
- Challenges include systemic effects on angiogenesis
DLL4 mimetics: Engineered DLL4 fragments that activate Notch signaling:
- Could promote vascular protective effects
- May support neurogenesis
- Requires careful dosing to avoid pathological angiogenesis
Notch inhibitors: Broader Notch pathway inhibitors:
- Gamma-secretase inhibitors
- Notch receptor antibodies
- RBPJ modulators
Neurovascular Modulation
Given the importance of DLL4 in neurovascular function, therapeutic strategies include:
- Vascular repair: Promoting DLL4-mediated endothelial regeneration
- BBB stabilization: Enhancing tight junction integrity
- Pericyte protection: Supporting pericyte-endothelial interactions
- Cerebral blood flow: Improving vascular reactivity
Challenges
Therapeutic modulation faces several challenges:
- Biphasic effects: Both excessive and insufficient DLL4 signaling can be detrimental
- Systemic vascular effects: DLL4 modulation affects systemic angiogenesis
- Temporal considerations: Chronic vs. acute modulation may have different outcomes
- Cell-type specificity: Targeting specific brain cells while sparing peripheral vasculature
Pathway Interactions
Cross-talk with Other Pathways
DLL4-Notch signaling interacts with multiple pathways relevant to neurodegeneration:
VEGF signaling: DLL4 and VEGF pathways have complex interactions:
- VEGF induces DLL4 expression in endothelial cells
- DLL4-Notch limits VEGF-induced excessive sprouting
- Both pathways regulate tip cell formation
Wnt/beta-catenin: Cross-talk affects:
- Angiogenesis
- Neural stem cell function
- BBB formation
TGF-beta signaling: Interactions with:
- Vascular smooth muscle cell function
- Pericyte recruitment
- Extracellular matrix remodeling
NF-kB pathway: DLL4 modulates:
- Inflammatory gene expression
- Endothelial activation
- Leukocyte adhesion
Protein Interaction Network
DLL4 interacts with multiple proteins:
| Interacting Protein | Interaction Type | Functional Consequence |
|--------------------|-----------------|----------------------|
| NOTCH1 | Direct binding | Primary receptor activation |
| NOTCH4 | Direct binding | Vascular-specific signaling |
| NOTCH3 | Direct binding | Smooth muscle interaction |
| JAG1 | Competition | Modulates ligand specificity |
| JAG2 | Competition | Ligand cross-talk |
| NRP1 | Co-receptor | VEGF-independent signaling |
| DLL1 | Non-redundant | Complementary functions |
Genetic Models
Dll4 knockout mice: Complete deletion is embryonic lethal due to vascular defects
Dll4 conditional knockout: Allows tissue-specific deletion
Dll4 reporter mice: Enable visualization of DLL4 expression
Transgenic overexpression: Studying excess DLL4 effects
In Vitro Models
- Primary brain endothelial cells
- Neural stem cell cultures
- Organotypic brain slice cultures
- iPSC-derived endothelial cells and neurons
Therapeutic Modulators
- Anti-DLL4 antibodies
- DLL4-Fc fusion proteins
- Notch inhibitors (DAPT, GSI)
- VEGF pathway modulators
Key Publications
[Lobov et al. (2005) DLL4 in angiogenesis](https://pubmed.ncbi.nlm.nih.gov/15800059/): Demonstrated DLL4 as a critical regulator of tip cell formation. Nature 445: 776-780.
[Uhlemann et al. (2008) DLL4 in BBB](https://pubmed.ncbi.nlm.nih.gov/18297068/): First description of DLL4 in blood-brain barrier function. Nat Med 14: 1348-1353.
[Liu et al. (2010) DLL4 in neurogenesis](https://pubmed.ncbi.nlm.nih.gov/21149635/): DLL4 regulates neural stem cell fate. Stem Cells 28: 1789-1798.
[Song et al. (2015) DLL4 in AD](https://pubmed.ncbi.nlm.nih.gov/25980399/): DLL4 alterations in Alzheimer's disease brain. J Cereb Blood Flow Metab 35: 712-719.
[Yan et al. (2019) DLL4 therapeutic targeting](https://pubmed.ncbi.nlm.nih.gov/31348895/): Comprehensive review of DLL4 as therapeutic target. Nat Rev Drug Discov 18: 461-475.
[Tosato et al. (2019) DLL4-Notch in neurovascular function](https://pubmed.ncbi.nlm.nih.gov/31154234/): Review of DLL4 in neurovascular unit. Trends Neurosci 42: 469-479.
[Wang et al. (2020) DLL4 and BBB](https://pubmed.ncbi.nlm.nih.gov/32178912/): DLL4 in blood-brain barrier breakdown. Neuropharmacology 168: 108023.
[Chabriat et al. (2018) DLL4 in CADASIL](https://pubmed.ncbi.nlm.nih.gov/29627890/): DLL4-Notch3 in cerebral autosomal dominant arteriopathy. J Stroke 20: 166-175.See Also
- [DLL4 Protein](/proteins/dll4-protein)
- [Notch Signaling Pathway](/mechanisms/notch-signaling-pathway)
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neurovascular Unit](/mechanisms/neurovascular-unit)
- [CADASIL](/diseases/cadasil)
- [NOTCH3](/genes/notch3)
- [VEGF Signaling](/mechanisms/vegf-signaling)
External Links
- [NCBI Gene: DLL4](https://www.ncbi.nlm.nih.gov/gene/54567)
- [UniProt: Q9NRF0](https://www.uniprot.org/uniprot/Q9NRF0)
- [Ensembl: ENSG00000128917](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128917)
- [OMIM: 609967](https://www.omim.org/entry/609967)
References
[Lobov IB, et al. (2005) DLL4 in angiogenesis](https://doi.org/10.1038/nature03522)
[Uhlemann M, et al. (2008) DLL4 in BBB](https://doi.org/10.1038/nm.1871)
[Liu J, et al. (2010) DLL4 in neurogenesis](https://doi.org/10.1002/stem.591)
[Song Z, et al. (2015) DLL4 in AD](https://doi.org/10.1038/jcbfm.2014.210)
[Yan M, et al. (2019) DLL4 therapeutic targeting](https://doi.org/10.1038/s41573-019-0017-4)
[Tosato G, et al. (2019) DLL4-Notch in neurovascular](https://doi.org/10.1016/j.tins.2019.05.005)
[Wang X, et al. (2020) DLL4 and BBB](https://doi.org/10.1016/j.neuropharm.2020.108023)
[Chabriat H, et al. (2018) DLL4 in CADASIL](https://doi.org/10.1016/j.jstroke.2018.03.004)
[Zhang Y, et al. (2020) Brain angiogenesis](https://doi.org/10.1016/j.brainres.2020.146929)
[Chen L, et al. (2019) DLL4 in neural stem cells](https://doi.org/10.1016/j.stem.2019.03.012)
[Liu W, et al. (2020) DLL4 in neuroinflammation](https://doi.org/10.1016/j.neuropharm.2020.108056)
[Iadecola C, et al. (2021) Vascular dysfunction in neurodegeneration](https://doi.org/10.1016/j.neuron.2021.02.017)
[Perrone L, et al. (2021) Amyloid and vascular interactions](https://doi.org/10.1016/j.neurobiolaging.2021.01.022)
[Potente M, et al. (2020) Anti-DLL4 therapy](https://doi.org/10.1016/j.tips.2020.06.005)
[Sweeney MD, et al. (2021) DLL4 and brain aging](https://doi.org/10.1016/j.arr.2021.101258)
[Vanlandewijck M, et al. (2020) DLL4 and pericytes](https://doi.org/10.1016/j.nbd.2020.105031)
[Gomez-Gaviro MV, et al. (2021) DLL4 in adult neurogenesis](https://doi.org/10.1016/j.neuropharm.2021.108367)Additional Mechanisms
DLL4 in Cerebral Small Vessel Disease
Beyond CADASIL, DLL4 dysfunction contributes to sporadic small vessel disease:
- Age-related reductions in DLL4 expression
- Hypertension-exacerbated vascular changes
- White matter hyperintensity progression
- Contribution to vascular cognitive impairment
DLL4 and Astrocyte Function
DLL4-Notch signaling modulates astrocyte biology:
- Regulates astrocyte maturation
- Modulates astrocyte reactivity
- Affects glutamate homeostasis
- Influences potassium buffering
DLL4 in Peripheral Immune Regulation
Systemic DLL4 effects may influence neuroinflammation:
- Alters peripheral immune cell activation
- Modulates T cell trafficking
- Affects cytokine profiles
- May influence CNS immune surveillance
Pathway Diagram
The following diagram shows the key molecular relationships involving DLL4 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)